Evidence map›Paper›PMID 24585267›Full record

Trial reportEuropean heart journal2014

Diuretic response in acute heart failure: clinical characteristics and prognostic significance.

Mattia A E Valente, Adriaan A Voors, Kevin Damman, Dirk J Van Veldhuisen, Barrie M Massie, Christopher M O'Connor, Marco Metra, Piotr Ponikowski, John R Teerlink, Gad Cotter and 7 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04298229 (A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure), which is not on this map. Cited by 160 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298229 phase3completedstarted 2020, after this paper: background citation

A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure

Ran2020Enrolled240Registered outcomes3Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Heart FailureArmsDapagliflozin 10 mg, Protocolized Diuretic Therapy
Open the trial in the graph
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024 · on this map
    Pooled it
  4. Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Mattia A E ValenteDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands a.a.voors@umcg.nl.
Kevin DammanDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Dirk J Van VeldhuisenDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Barrie M MassieUniversity of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Christopher M O'ConnorDuke University Medical Center, Durham, NC, USA.
Marco MetraUniversity of Brescia, Brescia, Italy.
Piotr PonikowskiMedical University, Clinical Military Hospital, Wroclaw, Poland.
John R TeerlinkUniversity of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Gad CotterMomentum Research, Durham, NC, USA.
Beth DavisonMomentum Research, Durham, NC, USA.
John G F ClelandUniversity of Hull, Kingston upon Hull, UK.
Michael M GivertzBrigham and Women's Hospital, Boston, MA, USA.
Daniel M BloomfieldMerck Research Laboratories, Rahway, NJ, USA.
Mona FiuzatDuke University Medical Center, Durham, NC, USA.
Howard C DittrichCardiovascular Research Center, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Hans L HillegeDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands Department of Epidemiology, University Medical Center Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimDiminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome. METHODS AND

resultsWe examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial. Day 4 response was used to allow maximum differentiation in responsiveness and tailoring of diuretic doses to clinical response, following sensitivity analyses. We investigated predictors of diuretic response and relationships with outcome. The median diuretic response was -0.38 (-0.80 to -0.13) kg/40 mg furosemide. Poor diuretic response was independently associated with low systolic blood pressure, high blood urea nitrogen, diabetes, and atherosclerotic disease (all P < 0.05). Worse diuretic response independently predicted 180-day mortality (HR: 1.42; 95% CI: 1.11-1.81, P = 0.005), 60-day death or renal or cardiovascular rehospitalization (HR: 1.34; 95% CI: 1.14-1.59, P < 0.001) and 60-day HF rehospitalization (HR: 1.57; 95% CI: 1.24-2.01, P < 0.001) in multivariable models. The proposed metric-weight loss indexed to diuretic dose-better captures a dose-response relationship. Model diagnostics showed diuretic response provided essentially the same or slightly better prognostic information compared with its individual components (weight loss and diuretic dose) in this population, while providing a less biased, more easily interpreted signal.

conclusionsWorse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure, and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.

Indexed as

Acute DiseaseAgedAnalysis of VarianceAtherosclerosisBumetanideDiabetes ComplicationsDiureticsDose-Response Relationship, DrugDrug ResistanceDyspneaFemaleFurosemideHeart FailureHumansHypotensionMaleBumetanideDiureticsFurosemiderolofyllineSulfonamidesTorsemideXanthinesCardiorenal syndromeDiuretic resistanceDiureticsHeart failureMortalityPrognosisRehospitalizationRenal dysfunctionWorsening renal function

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.